Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Get Free Report) insider John Militello sold 3,726 shares of the stock in a transaction on Friday, February 13th. The stock was sold at an average price of $3.31, for a total transaction of $12,333.06. Following the transaction, the insider directly owned 92,176 shares in the company, valued at $305,102.56. The trade was a 3.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Rocket Pharmaceuticals Price Performance
Shares of NASDAQ:RCKT opened at $3.45 on Thursday. The stock has a market capitalization of $373.36 million, a P/E ratio of -1.53 and a beta of 0.48. The business has a 50-day moving average of $3.49 and a two-hundred day moving average of $3.39. Rocket Pharmaceuticals, Inc. has a fifty-two week low of $2.19 and a fifty-two week high of $11.09. The company has a debt-to-equity ratio of 0.06, a current ratio of 7.30 and a quick ratio of 7.30.
Institutional Trading of Rocket Pharmaceuticals
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Corient Private Wealth LLC bought a new position in shares of Rocket Pharmaceuticals during the 4th quarter worth about $98,000. Virtus Investment Advisers LLC grew its position in Rocket Pharmaceuticals by 111.7% during the fourth quarter. Virtus Investment Advisers LLC now owns 78,474 shares of the biotechnology company's stock worth $275,000 after buying an additional 41,410 shares in the last quarter. Opaleye Management Inc. bought a new position in Rocket Pharmaceuticals during the fourth quarter valued at about $3,352,000. Engineers Gate Manager LP raised its holdings in Rocket Pharmaceuticals by 34.5% in the 4th quarter. Engineers Gate Manager LP now owns 96,009 shares of the biotechnology company's stock valued at $337,000 after acquiring an additional 24,603 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC bought a new stake in shares of Rocket Pharmaceuticals in the 4th quarter worth approximately $524,000. 98.39% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several equities analysts have commented on the company. Wedbush reiterated an "outperform" rating and set a $16.00 price target on shares of Rocket Pharmaceuticals in a report on Friday, November 7th. Bank of America decreased their price objective on shares of Rocket Pharmaceuticals from $10.00 to $8.00 and set a "buy" rating for the company in a report on Tuesday, November 18th. TD Cowen upgraded shares of Rocket Pharmaceuticals to a "hold" rating in a report on Friday, December 19th. JPMorgan Chase & Co. lowered shares of Rocket Pharmaceuticals from a "neutral" rating to an "underweight" rating in a research report on Tuesday, November 18th. Finally, Morgan Stanley set a $5.00 price target on shares of Rocket Pharmaceuticals in a report on Thursday, January 8th. Eight research analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $14.36.
Read Our Latest Stock Analysis on Rocket Pharmaceuticals
Key Stories Impacting Rocket Pharmaceuticals
Here are the key news stories impacting Rocket Pharmaceuticals this week:
- Positive Sentiment: Morgan Stanley flagged Rocket as a potential beneficiary of a 2026 biotech-sector recovery, highlighting the company among small-to-mid cap names that could outperform (despite lowering its price target from $7 to $5 and keeping an Equal Weight rating). This note can attract buyer interest on hopes of sector-wide momentum. Morgan Stanley Names Rocket Pharmaceuticals as Key Beneficiary
- Neutral Sentiment: Rocket is expected to report quarterly earnings on Thursday; the upcoming release is a near-term catalyst that could increase volatility depending on revenue, guidance, or pipeline updates. Investors often trade cautiously into earnings. Rocket Pharmaceuticals Expected to Announce Quarterly Earnings
- Negative Sentiment: Several insiders sold stock on Feb. 13 (CEO Gaurav Shah sold 12,279 shares at an average $3.31; General Counsel Martin Wilson and director John Militello also reported sales). Multiple Form 4s reduce insider ownership modestly and can be interpreted negatively by investors sensitive to insider activity. Gaurav Shah Form 4 (SEC)
About Rocket Pharmaceuticals
(
Get Free Report)
Rocket Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing gene therapies for rare, inherited pediatric diseases. The company employs a proprietary adeno-associated virus (AAV) and lentiviral vector platform to deliver functional copies of genes in patients with genetic deficiencies. Its programs target a spectrum of disorders, including Fanconi anemia, leukocyte adhesion deficiency type I and Danon disease, with the goal of delivering one-time treatments that address the underlying causes of disease rather than merely managing symptoms.
The company's pipeline comprises multiple product candidates in various stages of development.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
